Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T13:35:45.769Z.
Calculation as of: 2026-10-06T13:35:45.769Z.
Quote observation: 2026-10-06T13:30:19.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 5a667a199b47e7e336467208d2f6772290b800d1a0ab6507ee3a182ebbb9f075
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
BGM Group Ltd.
Market Cap
$117.87M
EV/EBIT Ratio
N/A
| NAME | MARKET CAP | EV/EBIT RATIO |
|---|---|---|
| BGM Group Ltd. (BGM) | $117.87M | N/A |
| Caribou Biosciences, Inc. (CRBU)vs › | $118.02M | N/A |
| Foghorn Therapeutics Inc. (FHTX)vs › | $117.43M | N/A |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $120.44M | N/A |
| TuHURA Biosciences, Inc. (HURA)vs › | $121.00M | N/A |
| Genelux Corporation (GNLX)vs › | $115.69M | N/A |
| Aardvark Therapeutics, Inc. Common Stock (AARD)vs › | $115.44M | N/A |
| Coya Therapeutics, Inc. (COYA)vs › | $114.00M | N/A |
| LENZ Therapeutics, Inc. (LENZ)vs › | $112.88M | N/A |
| enGene Holdings Inc. (ENGN)vs › | $125.27M | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
